EGFR and adenocarcinoma: Finally, about 2–15% of patients treated with EGFR-TKIs develop a histological transformation from adenocarcinoma to small cell lung cancer (SCLC), or rarely to squamous carcinoma, acquiring resistance to EGFR-TKIs.